A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression.
Protein Expr Purif · 2024
Last updated 2026-05-28Researchers developed a new method to produce semaglutide, a drug used to treat type 2 diabetes, that may lower costs and increase efficiency. The process combines solid-phase peptide synthesis with a bacterial expression system, achieving a yield of 100 milligrams per liter of culture. This approach avoids precipitation issues and simplifies purification, potentially enabling large-scale production of the drug.
AI summary of the abstract below.
| Journal | Protein Expr Purif, 2024 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 1.40 |
| NIH percentile | 62 |
| Molecules | semaglutide |
Abstract
Semaglutide is currently the most promising antidiabetic drug, especially for the treatment of type 2 diabetes mellitus, due to its excellent efficacy in glycemic control and weight loss. However, the production of semaglutide remains high cost, and high yield, low cost, and high purity still remains a challenge. Herein, we reported a convenient and high-yield strategy for the preparation of semaglutide through fragmented condensation coupling, involving solid-phase peptide synthesis of tetrapeptide and on-column refolding and on-column enzyme cleavage based inclusion body expression of LysArgGLP-1 (11-37) with fused protein tags in an X-Y-D4K-G pattern. The optimized N-terminal protein tag significantly boosts inclusion body expression level, while on-column refolding and on-column enzyme cleavage avoid precipitation, enhancing efficiency and yield together with one-step purification. The successful preparation of semaglutide is expected to achieve large-scale industrial production with low cost, high yield and high purity.
Verbatim abstract via PubMed 38527576 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.